CY2014003I2 - Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο - Google Patents

Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο

Info

Publication number
CY2014003I2
CY2014003I2 CY2014003C CY2014003C CY2014003I2 CY 2014003 I2 CY2014003 I2 CY 2014003I2 CY 2014003 C CY2014003 C CY 2014003C CY 2014003 C CY2014003 C CY 2014003C CY 2014003 I2 CY2014003 I2 CY 2014003I2
Authority
CY
Cyprus
Prior art keywords
miccule
echinocandin
pharmaceutical forms
forming surfactants
surfactants
Prior art date
Application number
CY2014003C
Other languages
English (en)
Other versions
CY2014003I1 (el
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22403808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2014003(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY2014003I2 publication Critical patent/CY2014003I2/el
Publication of CY2014003I1 publication Critical patent/CY2014003I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CY2014003C 1999-03-03 2014-01-16 Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο CY2014003I1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12262399P 1999-03-03 1999-03-03
EP00910391A EP1156782B1 (en) 1999-03-03 2000-03-02 Echinocandin pharmaceutical formulations containing micelle-forming surfactants

Publications (2)

Publication Number Publication Date
CY2014003I2 true CY2014003I2 (el) 2015-12-09
CY2014003I1 CY2014003I1 (el) 2015-12-09

Family

ID=22403808

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131101042T CY1114631T1 (el) 1999-03-03 2013-11-21 Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
CY2014003C CY2014003I1 (el) 1999-03-03 2014-01-16 Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20131101042T CY1114631T1 (el) 1999-03-03 2013-11-21 Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο

Country Status (19)

Country Link
US (2) US6960564B2 (el)
EP (2) EP1582204B1 (el)
JP (2) JP4936595B2 (el)
KR (1) KR100613136B1 (el)
CN (1) CN100335122C (el)
AT (1) ATE294571T1 (el)
AU (1) AU776782C (el)
BR (1) BRPI0009249B8 (el)
CA (1) CA2362481C (el)
CY (2) CY1114631T1 (el)
DE (1) DE60019902D1 (el)
DK (1) DK1582204T3 (el)
ES (1) ES2433678T3 (el)
HK (1) HK1040062A1 (el)
IL (1) IL145185A0 (el)
PT (1) PT1582204E (el)
RU (1) RU2250763C2 (el)
WO (1) WO2000051564A1 (el)
ZA (1) ZA200108002B (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
AU766091B2 (en) 1998-12-09 2003-10-09 Eli Lilly And Company Purification of echinocandin cyclopeptide compounds
WO2000051564A1 (en) 1999-03-03 2000-09-08 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
IL145188A0 (en) 1999-03-03 2002-06-30 Lilly Co Eli Processes for making pharmaceutical oral ecb formulations and compositions
KR20020002476A (ko) 1999-03-03 2002-01-09 피터 지. 스트링거 결정질 에키노칸딘 암모늄염의 형성 및 음이온 교환
AU772633B2 (en) 1999-03-03 2004-05-06 Eli Lilly And Company Echinocandin/carbohydrate complexes
TWI233805B (en) 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1415648B1 (en) * 2001-07-13 2006-11-22 NanoCarrier Co., Ltd. Lyophilizing composition of drug-encapsulating polymer micelle and method for preparation thereof
JP2003342168A (ja) * 2002-05-24 2003-12-03 Nano Career Kk 注射用薬物含有ポリマーミセル製剤の製造方法
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
EP2422789B1 (en) * 2004-05-19 2017-11-22 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Injectable coposition comprising sodium deoxycholate
CN100579510C (zh) * 2006-04-13 2010-01-13 新疆维吾尔自治区包虫病临床研究所 新型前体胶束制剂及其生产方法
CA2692053A1 (en) * 2007-06-26 2008-12-31 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
MX2010012451A (es) * 2008-05-15 2010-12-07 Baxter Int Formulaciones farmaceuticas estables.
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
EP2521539A4 (en) * 2009-12-31 2014-11-26 Mannkind Corp INJECTABLE PREPARATIONS FOR PARENTERAL ADMINISTRATION
CN102618606B (zh) * 2011-01-30 2014-09-10 浙江海正药业股份有限公司 一种棘白菌素生物转化方法
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
CA2865791C (en) 2011-03-03 2019-10-08 Cidara Therapeutics, Inc. Antifungal agents and uses thereof
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
CN102488889B (zh) * 2011-09-26 2014-01-22 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
CN102488886B (zh) * 2011-09-26 2014-03-26 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
MX2014008390A (es) * 2012-01-12 2014-09-22 Celgene Corp Formulaciones de romidepsina y sus usos.
HRP20231151T1 (hr) * 2012-03-19 2024-01-05 Cidara Therapeutics, Inc. Režimi za doziranje spojeva iz klase ehinokandina
CN103570530B (zh) * 2012-07-26 2016-08-10 鲁南新时代生物技术有限公司 一种阿尼芬净侧链中间体的制备方法
CN112972378A (zh) * 2014-09-24 2021-06-18 艾瑞朗医疗公司 拟肽大环化合物及其制剂
EP3220954A4 (en) * 2014-11-19 2018-06-27 Gufic Biosciences Limited Process for preparation of parenteral formulation of anidulafungin
CN105641678A (zh) * 2014-12-03 2016-06-08 博瑞生物医药（苏州）股份有限公司 阿尼芬净胃肠外制剂及制备方法
PL3058958T3 (pl) 2015-02-23 2019-02-28 Selectchemie Ag Kompozycja anidulafunginy
GR1008818B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
JP7063803B2 (ja) * 2015-08-28 2022-05-09 カリウェイ バイオファーマシューティカルズ カンパニー リミテッド 局所脂肪の減少に用いる医薬組成物およびその用途
WO2017037232A1 (en) * 2015-09-02 2017-03-09 Xellia Pharmaceuticals Aps Anidulafungin formulations
EP3430400B1 (en) 2016-03-16 2023-06-21 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
CN111050798A (zh) 2017-07-12 2020-04-21 奇达拉治疗公司 用于治疗真菌感染的组合物和方法
CN109574811B (zh) * 2018-11-22 2021-12-24 中山大学 一种阿尼芬净侧链中间体对戊氧基三联苯甲酸的制备方法
CN109481665B (zh) * 2018-12-05 2019-08-06 广州迈达康医药科技有限公司 一种注射用阿尼芬净复溶药剂及其制备方法
US20220409544A1 (en) 2019-11-22 2022-12-29 Leiutis Pharmaceuticals Llp Stable parenteral formulations of duloxetine
KR20250088769A (ko) 2022-10-25 2025-06-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 에키노칸딘 유사체의 약학 조성물 및 이의 제조방법

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US3293482A (en) * 1962-06-21 1966-12-20 Rca Corp Plural output traveling wave tube
JPS5134916B2 (el) * 1974-03-06 1976-09-29
JPS5668616A (en) * 1979-11-08 1981-06-09 Yukio Kimura Preparation of antibiotic composition
CA1170598A (en) 1979-12-13 1984-07-10 Bernard J. Abbott Process for the preparation of cyclic peptide nuclei
US4299763A (en) * 1979-12-13 1981-11-10 Eli Lilly And Company A-30912B Nucleus
CA1183127A (en) 1979-12-13 1985-02-26 Manuel Debono Process for the preparation of derivatives of cyclic peptide nuclei
US4293483A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
US4293489A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
US4304716A (en) * 1979-12-13 1981-12-08 Eli Lilly And Company S 31794/F-1 Nucleus
US4293482A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company A-30912A Nucleus
US4320052A (en) * 1979-12-13 1982-03-16 Eli Lilly And Company Derivatives of A-30912A nucleus
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
US4876241A (en) * 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
US5000000A (en) * 1988-08-31 1991-03-19 University Of Florida Ethanol production by Escherichia coli strains co-expressing Zymomonas PDC and ADH genes
DK173802B1 (da) 1988-09-12 2001-11-05 Merck & Co Inc Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US4927831A (en) 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
AU617541B2 (en) 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
JP2844351B2 (ja) * 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
JPH03240727A (ja) * 1990-02-15 1991-10-28 Toyo Jozo Co Ltd ニューモシスチス・カリニ肺炎治療剤
CA2037957A1 (en) 1990-03-12 1991-09-13 Merck & Co., Inc. N-acylated cyclohexapeptide compounds
GB2241956A (en) 1990-03-16 1991-09-18 Merck & Co Inc N-acylated cyclohexapeptide compounds
US5310726A (en) 1990-03-19 1994-05-10 Merck & Co., Inc. Lipopeptide compounds
IE910892A1 (en) 1990-03-19 1991-09-25 Merck & Co Inc Lipopeptide compounds
US5330973A (en) 1990-03-19 1994-07-19 Merck & Co., Inc. Lipopeptide derivatives
IL97347A0 (en) 1990-03-19 1992-05-25 Merck & Co Inc Lipopeptide derivatives and antimicrobial compositions containing them
US5386009A (en) 1990-03-19 1995-01-31 Merck & Co. Inc. Lipopeptide derivatives
US5049546A (en) 1990-03-19 1991-09-17 Merck & Co., Inc. Antibiotic agents
EP0460882B1 (en) 1990-06-07 1996-07-24 Eli Lilly And Company Lipopeptide deacylase
IL98506A (en) 1990-06-18 1996-09-12 Fujisawa Pharmaceutical Co Cyclic peptide antibiotics processes for the preparation thereof and pharmaceutical compositions containing them
US5198421A (en) * 1991-04-26 1993-03-30 Merck & Co., Inc. Phosphorylated cyclic lipopeptide
EP0486011A3 (en) 1990-11-16 1992-07-15 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition against pneumocystis carinii
US5369093A (en) 1991-03-15 1994-11-29 Merck & Co., Inc. Lipopeptide derivatives
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5136783A (en) * 1991-05-23 1992-08-11 Blount, Inc. Chain saw sprocket
US5233023A (en) 1991-07-30 1993-08-03 Merck & Co., Inc. Process for phosphate ester compounds of certain cyclohexapeptides
JPH05271097A (ja) * 1991-10-07 1993-10-19 Asahi Chem Ind Co Ltd アクレアシン類の可溶化剤および医薬組成物
US6384013B1 (en) * 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5965525A (en) * 1992-03-19 1999-10-12 Eli Lilly And Company Cyclic peptide antifungal agents
MY136593A (en) * 1992-03-19 2008-10-31 Lilly Co Eli Cyclic peptide antifungal agents and process for preparation thereof
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
DE69232220D1 (de) 1992-09-22 2002-01-03 Takeo Takayanagi Kohlenhydrate-Komplexe zur Vernichtung von Krebszellen
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
JPH06172205A (ja) * 1992-12-11 1994-06-21 Asahi Chem Ind Co Ltd アクレアシン類含有脂肪乳剤
US6268338B1 (en) * 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
AU674233B2 (en) * 1993-05-04 1996-12-12 Merck & Co., Inc. Cyclohexapeptidyl aminoalkyl ethers
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5541160A (en) * 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5646111A (en) 1995-04-07 1997-07-08 Eli Lilly And Company Cyclic peptide antifungal Agents
US5786325A (en) 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
US5618787A (en) * 1995-05-26 1997-04-08 Eli Lilly And Company Cyclic peptide antifungal agents
US5652213A (en) * 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
US5629290A (en) * 1995-05-26 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5629289A (en) 1995-07-25 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US5693611A (en) * 1996-02-01 1997-12-02 Eli Lilly And Company Cyclic peptide antifungal agents
WO1997027864A1 (en) 1996-02-01 1997-08-07 Eli Lilly And Company Cyclic peptide antifungal agents
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
AR006598A1 (es) * 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
FR2755857B1 (fr) 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AUPO381496A0 (en) 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
AU6014098A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Aerosolized hydrophobic drug
AUPO691897A0 (en) * 1997-05-21 1997-06-12 Fujisawa Pharmaceutical Co., Ltd. New compound
WO1999006062A1 (en) 1997-08-04 1999-02-11 Eli Lilly And Company Cyclic peptide antifungal agents
US5972996A (en) * 1997-08-22 1999-10-26 Merck & Co., Inc. 4-cyano-4-deformylsordarin derivatives
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
CA2255140A1 (en) 1997-12-23 1999-06-23 Eli Lilly And Company Echinocandin binding domain of 1,3-.beta.-glucan synthase
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6451349B1 (en) * 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
WO2000011023A2 (en) 1998-08-20 2000-03-02 Eli Lilly And Company Ring modified cyclic peptide analogs
EP1107982B1 (en) 1998-08-28 2004-05-19 Eli Lilly & Company Reversible boron complexes of 1,2-(cis)-diol cyclic peptides
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU766091B2 (en) * 1998-12-09 2003-10-09 Eli Lilly And Company Purification of echinocandin cyclopeptide compounds
EP1140991A1 (en) 1998-12-16 2001-10-10 Eli Lilly And Company Cyclic peptide antifungal agents
AU2189500A (en) 1998-12-16 2000-07-03 Eli Lilly And Company Cyclic peptide antifungal agents having a sugar substituent
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
KR20020002476A (ko) 1999-03-03 2002-01-09 피터 지. 스트링거 결정질 에키노칸딘 암모늄염의 형성 및 음이온 교환
AU772633B2 (en) * 1999-03-03 2004-05-06 Eli Lilly And Company Echinocandin/carbohydrate complexes
WO2000051564A1 (en) 1999-03-03 2000-09-08 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
IL145188A0 (en) * 1999-03-03 2002-06-30 Lilly Co Eli Processes for making pharmaceutical oral ecb formulations and compositions
US6258821B1 (en) * 1999-04-26 2001-07-10 Medimmune Oncology, Inc. Compositions comprising trimetrexate and methods of their synthesis and use
WO2003018051A1 (en) * 2001-08-27 2003-03-06 Vic Jira Anti-fungal composition
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products

Also Published As

Publication number Publication date
CY1114631T1 (el) 2015-12-09
EP1156782B1 (en) 2005-05-04
AU776782B2 (en) 2004-09-23
KR100613136B1 (ko) 2006-08-17
WO2000051564A8 (en) 2002-05-30
BRPI0009249B8 (pt) 2021-07-06
HK1040062A1 (zh) 2002-05-24
US20030054981A1 (en) 2003-03-20
CA2362481C (en) 2008-11-04
RU2250763C2 (ru) 2005-04-27
IL145185A0 (en) 2002-06-30
BRPI0009249A (pt) 2001-11-20
JP4755464B2 (ja) 2011-08-24
CA2362481A1 (en) 2000-09-08
AU3249100A (en) 2000-09-21
WO2000051564A1 (en) 2000-09-08
BRPI0009249B1 (pt) 2011-11-29
HK1074803A1 (en) 2005-11-25
EP1582204A3 (en) 2007-10-10
DE60019902D1 (de) 2005-06-09
US20050192213A1 (en) 2005-09-01
JP2002538095A (ja) 2002-11-12
ES2433678T3 (es) 2013-12-12
EP1582204B1 (en) 2013-09-25
US6960564B2 (en) 2005-11-01
PT1582204E (pt) 2013-11-25
EP1156782A1 (en) 2001-11-28
AU776782C (en) 2005-04-07
DK1582204T3 (da) 2013-11-04
JP2005325142A (ja) 2005-11-24
EP1582204A2 (en) 2005-10-05
JP4936595B2 (ja) 2012-05-23
ZA200108002B (en) 2003-06-25
CN1345229A (zh) 2002-04-17
US7709444B2 (en) 2010-05-04
ATE294571T1 (de) 2005-05-15
KR20010111570A (ko) 2001-12-19
CY2014003I1 (el) 2015-12-09
CN100335122C (zh) 2007-09-05

Similar Documents

Publication Publication Date Title
CY2014003I2 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
NO20071303L (no) Farmasoytiske preparater
PT1207867E (pt) Formas de administracao farmaceuticas orais retardadas contendo tramadol
ITTO20010008A0 (it) Formulazione farmaceutica
NO20033556D0 (no) Farmasöytiske preparater
PT1221918E (pt) Administracao de drogas sub-tenon
NO20022970L (no) Hydrogel-drevet medikamentdoseringsform
NO20030030L (no) Farmasöytiske blandinger av östrogene midler
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
NO20030627L (no) Hydrogel-drevet medikament doseringsform
EE200200038A (et) Konservitud farmatseutilised preparaadid
EE200200393A (et) Glüburiidi ravimkoostis
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
NO20030139D0 (no) Farmasöytiske preparater inneholdende DDS forbindelser
DK1466615T3 (da) Farmaceutisk præparat
ATE332132T1 (de) Verbesserte arzneizubereitungen enthaltend ritonavir
NO20014926L (no) Farmasöytiske forbindelser
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
DE69926012D1 (de) Arzneizubereitungen
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20016430L (no) Farmasöytisk kompleks
DE69906934D1 (de) Arzneizubereitungen
NO20004816D0 (no) Ny farmasøytisk formulering
ID30381A (id) Penggunaan arilalkanoilpiridazina